Related Experiment Videos
Thrombin and antithrombotic therapy in interventional cardiology
1Catheterization Laboratory, Thoraxcenter, Erasmus University, Rotterdam, The Netherlands.
Insights
Percutaneous transluminal coronary angioplasty has improved success rates, but restenosis remains a challenge. Research is focusing on thrombin inhibition to prevent reocclusion and improve long-term outcomes in angioplasty patients.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Pharmacology
Background:
- Percutaneous transluminal coronary angioplasty (PTCA) offers high procedural success but is limited by early and late reocclusion.
- Despite technological advances, restenosis (late renarrowing) affects 15%-40% of patients, leading to angina recurrence.
Purpose of the Study:
- To review the challenges of restenosis after PTCA.
- To explore the role of thrombin in angioplasty-induced vascular injury.
- To discuss current pharmacologic strategies targeting thrombin to prevent reocclusion.
Main Methods:
- Review of multicenter randomized trials and animal experimental work.
- Focus on understanding the restenosis phenomenon and thrombin's role.
- Evaluation of antithrombotic medications targeting thrombin.
Main Results:
- PTCA procedural success rates are high (90%-95%), with low complication rates (4%-5%).
- Late reocclusion and angina recurrence remain significant issues in 15%-40% of patients.
- Thrombin is identified as a key factor in vascular injury post-angioplasty.
Conclusions:
- No major breakthroughs in preventing restenosis have been reported, but understanding has progressed.
- Pharmacologic research is concentrating on direct thrombin inhibition.
- Clinical trials are crucial to assess the safety, efficacy, and potential side effects of new antithrombotic therapies.
Abstract:
Despite developments in percutaneous transluminal coronary angioplasty, the success of this treatment method remains clouded by early and late reocclusion. Increased experience, advances in technology, and the introduction of adjunctive devices have contributed to a higher procedural success rate (90% to 95%) and to a lower complication rate (4% to 5%), in spite of the expanded indications for angioplasty. Late renarrowing of the treated coronary artery, in combination with recurrence of angina pectoris, occurs in 15% to 40% of angioplasty patients. Several multicenter randomized trials of pharmaceutical agents have been conducted or are in progress, in an effort to diminish the rate of late reocclusion. No major breakthrough has been reported, although a clear progression has been made in the understanding of the restenosis phenomenon. It is evident that thrombin plays a detrimental role in the vascular wall injury resulting from angioplasty procedures. Current pharmacologic research concentrates on direct inhibition of prothrombin conversion and thrombus formation. Animal experimental work in this field is encouraging, and the results of clinical trials will elucidate important questions about the safety, efficacy, and immuno-allergic potential of modern antithrombotic medication.